PAT-DX3 Cell Line Selected

Quarterly Activities Report and 4C

R&D Tax Refund

PAT-DX1 Engineering Update

$7.8m Capital Raise

Change of Company Secretary

Quarterly Activities Report and 4C Quarterly Cash Flow Report

Patrys PATDX3 antibody drug conjugate significantly increases survival in animal model

Patrys AGM – 5th Nov 2021

Patrys demonstrates potential for deoxmabs in antibody drug conjugates (ADCs)